Please login to the form below

Not currently logged in
Email:
Password:

Gilead

This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.

Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19

Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has granted a rapid approval of a supplemental drug application for Veklury (remdesivir) for the treatment of non-hospitalised ... Commenting on the approval, Daniel O’Day,

Latest news

More from news
Approximately 192 fully matching, plus 393 partially matching documents found.

Latest Intelligence

  • Setting up for success in a post-Brexit, post-pandemic Britain Setting up for success in a post-Brexit, post-pandemic Britain

    and running, ahead of our UK marketing authorisation in IBD, through our partnership with Gilead. ... With a focus on inflammatory and fibrotic conditions, we have submitted a marketing application through our partnership with Gilead for a new treatment

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and

  • The search for effective drug treatments for COVID-19 The search for effective drug treatments for COVID-19

    The European Commission has signed a joint procurement agreement for Gilead’s COVID-19 antiviral treatment remdesivir. ... Since January, Gilead has taken multiple steps to ramp up production and rapidly build supply in recognition of the lengthy

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.

  • Working together against COVID-19 Working together against COVID-19

    There were questions asked directly to Gilead, and also peers, about Compassionate Use and Extended Access. ... Subsequently, Gilead dropped remdesivir’s orphan drug designation based on its potential as a coronavirus treatment.

More from intelligence
Approximately 5 fully matching, plus 53 partially matching documents found.

Latest appointments

More from appointments
Approximately 6 fully matching, plus 21 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 15 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....